Answers are grounded in this paper and cite their sources.
Most publications over the past year that are relevant to the topic of antipsychotic drug treatment were concerned with the newer, atypical antipsychotic drugs, and the present review reflects this emphasis. Accordingly, the latest data on safety and efficacy are discussed for clozapine, risperidone, olanzapine, amisulpride, quetiapine and zotepine. The effects of the new antipsychotics on neurocognition have been a topic of interest for several years, but it has been difficult to draw firm conclusions from the diverse studies. Several useful reviews are now available, along with important and well controlled new studies. As discussed here, these advance our understanding in this area and support the opinion that the new antipsychotics have individual advantages over conventional drugs. Positron emission tomography and single-photon emission tomography ligand-binding studies of these drugs are also described, because they provide useful information linking dose, D2-receptor occupancy and clinical response. A second emphasis of the review concerns the practicalities of treatment with both conventional and the newer antipsychotics. The latest information regarding the effects of abrupt discontinuation of antipsychotic medication and the treatment of refractory schizophrenia is appraised. Finally, the vexing question of how prolonged duration of untreated psychosis might adversely affect prognosis is considered in the light of several new papers.
No takes yet. Share an insight, caveat, or question.
Barnes et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: